Noticias y vídeos - DYADIC INTL INC

Expanded ZAPI Program and Positive Preliminary Results from ZAPI Animal Study New Collaboration Agreement with Top Ten Pharmaceutical Company Expanded Research Relationship with Leading Pharmaceutical Company IIBR Collaboration Achieved Expression of Fc-fusion Enzyme to Counter Biological Attacks Glycoengineering Data Reinforces Company's Accelerated Glyco Strategy Two New Patent Applications JUPITER, FL / ACCESSWIRE / January 6, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company")...

JUPITER, FL / ACCESSWIRE / October 30, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, today announced that it will report its financial results for the quarter ended September 30, 2019 after the...

JUPITER, FL / ACCESSWIRE / October 10, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb will be attending and presenting...

JUPITER, FL / ACCESSWIRE / September 4, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb will be presenting at Janney...

JUPITER, FL / ACCESSWIRE / August 21, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb and Ping Rawson, Chief Financial...

New Fully Funded Research Collaboration With a Top Tier Pharmaceutical Company Expanded Technology Platform Through Multiple Collaborations and Sublicensing Agreements Robust Scientific Data Reported Up listed to the Nasdaq Capital Market and Joined Russell Microcap ® Index JUPITER, FL / ACCESSWIRE / August 13, 2019 / Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to...

JUPITER, FL / ACCESSWIRE / July 30, 2019 / Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, today announced that it will report its financial results for the quarter ended June 30, 2019 after the...

JUPITER, FLORIDA / ACCESSWIRE / July 5, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global platform biotechnology company, announced today that it has extended its research and development contract ("Contract") through June 2022 with VTT Technical Research Centre of Finland Ltd. ("VTT"), a world leading synthetic biology research and development organization. Under the terms of this extended multi-year agreement, Dyadic will provide funding to VTT to continue...

JUPITER, FL / ACCESSWIRE / July 2, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, announced today that the Company was added to the Russell Microcap ® Index effective July 1, as a...

JUPITER, FL / ACCESSWIRE / June 27, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, today announced the appointment of Ping Rawson to Chief Financial Officer, effective immediately. Ms. Rawson was...

JUPITER, FL / ACCESSWIRE / June 11, 2019 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scale today announced that its President and Chief Executive Officer, Mark Emalfarb, other members of the...

JUPITER, FL / ACCESSWIRE / May 17, 2019 / Dyadic International, Inc. (the ''Company'') (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb will attend and present at the...

Trading as DYAI on NASDAQ Capital Market as of April 17 New fully-funded proof-of-concept research collaborations with two top twenty-five pharmaceutical companies Sub-licensing agreements with Luina Bio and Alphazyme Collaboration with Serum Institute of India to develop and manufacture up to twelve antibodies and vaccines Execution of multiple strategic research initiatives further reinforces strength of Dyadic's C1 gene expression platform, including exploring the use of C1 to produce...

DGAP-News: Dyadic International, Inc. / Key word(s): Miscellaneous Dyadic and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products and Vaccines 08.05.2019 / 15:37 The issuer is solely responsible for the content of this announcement. PUNE, INDIA and JUPITER, FL / ACCESSWIRE / May 8, 2019 / Dyadic International, Inc. (''Dyadic'') (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene...

PUNE, INDIA and JUPITER, FL / ACCESSWIRE / May 8, 2019 / Dyadic International, Inc. (''Dyadic'') (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, is pleased to announce a research and commercialization collaboration with Serum Institute of India...

JUPITER, FL / ACCESSWIRE / May 6, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products at flexible commercial scales, is pleased to announce a sub-licensing agreement entered into with Alphazyme LLC ("Alphazyme"), a biotech company focused...

JUPITER, FL / ACCESSWIRE / April 30, 2019 / Dyadic International, Inc. (''Dyadic'') (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, is pleased to announce it has entered into a worldwide sub-licensing agreement with Australian based drug...

JUPITER, FL / ACCESSWIRE / April 25, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, today announced that it will report its financial results for quarter ended March 31, 2019 after the market close on...

JUPITER, FL / ACCESSWIRE / April 15, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, is pleased to announce that its common stock has been approved to list on The Nasdaq Capital Market. Trading on the Nasdaq is expected to...

Dyadic International to Webcast, Live, at VirtualInvestorConferences.com April 4th Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com PR Newswire JUPITER, Fla., April 1, 2019 JUPITER, Fla. , April 1, 2019 /PRNewswire/ -- Dyadic International, Inc. (the "Company") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1...